USPTO serial 88368976
IVIG IS OUR MIDDLE NAME
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- THOMAS-RIGGS, LESLIE A
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with IVIG IS OUR MIDDLE NAME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott D. Woldow
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP1055 THOMAS JEFFERSON ST. NWSUITE 400WASHINGTON, DC 20007Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 016 | Printed materials, namely, newsletters, articles and case studies featuring immunoglobulin, immunodeficiency and neurological disorders; Printed publications, namely, brochures, booklets, newsletters, articles, case studies, and teaching materials in the field of immunoglobulin, immunodeficiency and neurological disorders; printed educational materials in the field of immunoglobulin, immunodeficiency and neurological disorders | ACTIVE | — |
| 035 | Healthcare education services, namely, promoting awareness of immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals to patients, caregivers and/or healthcare professionals | ACTIVE | — |
| 041 | Healthcare education services, namely, conducting educational programs for patients, caregivers and/or healthcare professionals concerning immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals; planning and conducting educational conventions and educational meetings related to immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals | ACTIVE | — |
| 044 | Providing a website featuring information in the field of immunoglobulin, immunodeficiency and neurological disorders, and corresponding treatments; Healthcare and healthcare information services, namely, providing information concerning immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals; Healthcare and healthcare information services, namely, providing information concerning patient lifestyle and wellness for patients, caregivers, parents, teachers, coaches and friends impacted by immunoglobulin, immunodeficiency and neurological disorders; Providing a website featuring information in the field of the diagnosis and treatment of immunoglobulin, immunodeficiency and neurological disorders; Providing links to the web sites of others featuring information about the diagnosis and treatment of immunoglobulin, immunodeficiency and neurological disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CSL Behring AG
- Other trademarks owned by CSL Behring AG
- Other trademarks in Class 016
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 044
- Similar marks named IVIG IS OUR MIDDLE NAME
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 10, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 10, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 20, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 19, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 19, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 10, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 10, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 12, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 10, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 10, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 10, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 12, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 10, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 10, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 10, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 12, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 10, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 10, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 10, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 12, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 10, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 10, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 10, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 10, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 14, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 14, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 25, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 10, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 9, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 9, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 9, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 20, 2019 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jun 20, 2019 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jun 20, 2019 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Jun 20, 2019 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Jun 12, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 20, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 6, 2019 | NWAP | NEW APPLICATION ENTERED | — |